Otto Loewi Forschungszentrum

Research Focus: Chronic respiratory and pulmonary diseases

PI: Slaven Crnkovic

Focus: Smooth muscle cells in the pulmonary vasculature represent a heterogeneous cell population with a substantial potential to alter their behaviour depending on external cues. Some of these changes are linked and contribute to pathologic processes in several chronic lung diseases. Using the insights and knowhow gained previously within the framework of Ludwig Boltzmann Institute for Lung Vascular Research, our team is working to gain a deeper understanding how this diversity and plasticity is altered in disease state and molecular mechanisms that regulate these changes. To achieve this, we use a combination of molecular, cellular and phenotypic assays and lean heavily on state-of-the-art technologies with single cell resolution capability, including transcriptome analysis and multispectral imaging.

Networking: There is a continuous close collaboration with other members of the Otto Loewi Research Center, including Grazyna Kwapiszewska (Vascular remodelling) and Leigh Marsh (Immune cell interaction), and other researchers of the Medical University of Graz, including Gregor Gorkiewicz (Diagnostic & Research Institute of Pathology), Jörg Lindenmann (Division of Thoracic and Hyperbaric Surgery), Senka Holzer (Division of Cardiology). International collaboration partners include Vera Krymskaya (University of Pennsylvania, USA), Saverio Bellusci and Marek Bartkuhn (Justus Liebig University, Germany), Vinicio de Jesus Perez (Stanford University, USA), Miranda Sertic (University of Zagreb, Croatia).

Projekte

Inflammation and Metabolism in Pulmonary Hypertension are linked to skewed chromosome X Inactivation: new therapeutic options

  • Pulmonary arterial hypertension is a rare, but progressive fatal disease of the pulmonary circulation affecting primarily females. The INPHLeXIONS project consortium will investigate the underlying molecular mechanisms that lead to observed gender bias in this disease. Research groups from Austria, Germany and Canada will apply newly developed technologies to characterize aberrant inactivation of X chromosome-linked genes involved in inflammatory and metabolic processes. Gained insights will be used to develop and validate novel therapeutic options for pulmonary arterial hypertension.
  • Duration: 2020-2024
  • Funded by: FWF (I 4651)
  • Project partners: Roxane Paulin (Universitè Laval, Canada/AstraZeneca, Sweden), Konda Babu Kurakula (Max-Planck-Gesellschaft, Germany).

Otto Loewi Research Center

Slaven Crnkovic 
T: +43 316 385 73859

Team